FIGURE 2.

Effect of Bryo-1 on the activation of NF-κB in BMDCs. A, BMDCs from C57BL/6 mice were treated with Bryo-1 (10 ng/ml) or LPS (100 ng/ml). At the indicated time points, NF-κB DNA binding activity in nuclear extracts was determined by EMSA. Unt, untreated. B, specific formation of complexes, supershifted by anti-p50, anti-p65, and anti-c-Rel antibodies, are indicated by arrows. C and D, mutated oligonucleotide did not compete out the NF-κB complexes. F probe, free probe. E, competition assays demonstrated competing out of labeled NF-κB complexes in the presence of unlabeled wild-type NF-κB oligonucleotides.